Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation

被引:77
作者
Ploug, M
Ostergaard, S
Hansen, LBL
Holm, A
Dano, K
机构
[1] Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark
[2] Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark
关键词
D O I
10.1021/bi972787k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Binding of urokinase-type plasminogen activator (uPA) to its cellular receptor (uPAR) renders the cell surface a favored site for plasminogen activation. Recently, a 15-mer peptide antagonist of the uP4-uPAR interaction, with an IC50 value of 10 nM, was identified using phage display technology [Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) Proc. Natl. Acad. Sci. 91, 7129-7133]. In the present study, the molecular aspects of the interaction between this peptide and uPAR have been investigated. We have characterized the real-time receptor binding kinetics for the antagonist using surface plasmon resonance and identified critical residues by alanine replacements. The minimal peptide antagonist thus derived (SLNFSQYLWS) was rendered photoactivatable by replacing residues important for uPAR binding with photochemically active derivatives of phenylalanine containing either (trifluoromethyl)diazirine or benzophenone, These peptides incorporated covalently into purified soluble uPAR upon photoactivation, and this was inhibited by preincubation with receptor binding derivatives of uPA. The intact three-domain structure of uPAR was essential for efficient photoaffinity labeling. Proteolytic domain mapping using chymotrypsin revealed a specific labeling of both uPAR domain I and domains II + III dependent on the position of the photoprobe in the antagonist. On the basis of these studies, we propose the existence of a composite ligand binding site in uPAR combined of residues located in distinct structural domains. According to this model, a close spatial proximity between uPAR domain I and either domains II or III in intact uPAR is required for the assembly of this composite binding site. Since the receptor binding properties of the peptide antagonist closely mimic those of uPA itself, these two ligands presumably share a coincident binding site in uPAR.
引用
收藏
页码:3612 / 3622
页数:11
相关论文
共 47 条
[31]   STRUCTURE-FUNCTION-RELATIONSHIPS IN THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - COMPARISON TO OTHER MEMBERS OF THE LY-6 FAMILY AND SNAKE-VENOM ALPHA-NEUROTOXINS [J].
PLOUG, M ;
ELLIS, V .
FEBS LETTERS, 1994, 349 (02) :163-168
[32]   LIGAND INTERACTION BETWEEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR PROBED WITH 8-ANILINO-1-NAPHTHALENESULFONATE - EVIDENCE FOR A HYDROPHOBIC BINDING-SITE EXPOSED ONLY ON THE INTACT RECEPTOR [J].
PLOUG, M ;
ELLIS, V ;
DANO, K .
BIOCHEMISTRY, 1994, 33 (30) :8991-8997
[33]   A SOLUBLE FORM OF THE GLYCOLIPID-ANCHORED RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IS SECRETED FROM PERIPHERAL-BLOOD LEUKOCYTES FROM PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].
PLOUG, M ;
ERIKSEN, J ;
PLESNER, T ;
HANSEN, NE ;
DANO, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 208 (02) :397-404
[34]   CHEMICAL MODIFICATION OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR USING TETRANITROMETHANE - EVIDENCE FOR THE INVOLVEMENT OF SPECIFIC TYROSINE RESIDUES IN BOTH MOLECULES DURING RECEPTOR-LIGAND INTERACTION [J].
PLOUG, M ;
RAHBEKNIELSEN, H ;
ELLIS, V ;
ROEPSTORFF, P ;
DANO, K .
BIOCHEMISTRY, 1995, 34 (39) :12524-12534
[35]  
PLOUG M, 1993, J BIOL CHEM, V268, P17539
[36]  
PLOUG M, 1991, J BIOL CHEM, V266, P1926
[37]  
PLOUG M, 1992, BLOOD, V79, P1447
[38]   IMMUNOHISTOCHEMICAL DETECTION OF THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR IN HUMAN COLON-CANCER [J].
PYKE, C ;
RALFKIAER, E ;
RONNE, E ;
HOYERHANSEN, G ;
KIRKEBY, L ;
DANO, K .
HISTOPATHOLOGY, 1994, 24 (02) :131-138
[39]   CLONING AND EXPRESSION OF THE RECEPTOR FOR HUMAN UROKINASE PLASMINOGEN-ACTIVATOR, A CENTRAL MOLECULE IN CELL-SURFACE, PLASMIN DEPENDENT PROTEOLYSIS [J].
ROLDAN, AL ;
CUBELLIS, MV ;
MASUCCI, MT ;
BEHRENDT, N ;
LUND, LR ;
DANO, K ;
APPELLA, E ;
BLASI, F .
EMBO JOURNAL, 1990, 9 (02) :467-474
[40]   THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IS EXPRESSED BY KERATINOCYTES AT THE LEADING SKIN DURING REEPITHILIALIZATION [J].
ROMER, J ;
LUND, LR ;
ERIKSEN, J ;
PYKE, C ;
KRISTENSEN, P ;
DANO, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) :519-522